High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome

Human Reproduction

Volumn 26, Issue 1, 2011, Pages 227-234

  Chen, Mei Jou ^a   Chen, Chin Der ^a   Yang, Jehn Hsiahn ^a   Chen, Chi Ling ^b   Ho, Hong Nerng ^a   Yang, Wei Shiung ^b,c   Yang, Yu Shih ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

abdominal obesity; acne; dehydroepiandrosterone sulfate; insulin resistance; polycystic ovary syndrome

Indexed keywords

ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ACNE; ADULT; ARTICLE; BODY MASS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 78650712996     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deq308     Document Type: Article

References (43)

1. Acien P, Quereda F, Matallin P, Villarroya E, Lopez-Fernandez JA, Acien M, Mauri M, Alfayate R. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999;72:32-40.
2. Allolio B, Arlt W. DHEA treatment: myth or reality? Trends Endocrinol Metab 2002;13:288-294.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-488.
4. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989;320:559-565.
5. Bird CE, Masters V, Clark AF. Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. Clin Invest Med 1984; 7:119-122.
6. Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 2009; 91:1848-1852.
7. Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studiesofhyperandrogenic females. Diabetes 1991;40:693-700.
8. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol 2005;141:333-338.
9. Carmina E. Ovarian and adrenal hyperandrogenism. Ann N Y Acad Sci 2006;1092:130-137.
10. Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest 2007;30:111-116.
11. Chen MJ, Yang WS, Yang JH, Hsiao CK, Yang YS, Ho HN. Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS. Hum Reprod 2006;21:2266-2271.
12. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 2007;49:1442-1447.
13. Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008;23:952-957.
14. Christiansen JJ, Gravholt CH, Fisker S, Moller N, Andersen M, Svenstrup B, Bennett P, Ivarsen P, Christiansen JS, Jorgensen JO. Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. Eur J Endocrinol 2005; 152:77-85.
15. Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Milgrom E, Schaison G. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001;86:5060-5066.
16. De Heredia FP, Cerezo D, Zamora S, Garaulet M. Effect of dehydroepian-drosterone on protein and fat digestibility, body protein and muscular composition in high-fat-diet-fed old rats. Br J Nutr 2007;97:464-470.
17. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999;41:577-580.
18. Jakubowicz DJ, Beer NA, Beer RM, Nestler JE. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. J Clin Endocrinol Metab 1995;80:3373-3376.
19. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107-117.
20. Kameda W, Daimon M, Oizumi T, Jimbu Y, Kimura M, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M et al. Association of decrease in serum dehydroepiandrosterone sulfate levels with the progression to type 2 diabetes in men of a Japanese population: the Funagata Study. Metabolism 2005;54:669-676.
21. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, Polson DW, Reed MJ, Franks S. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32:213-220.
22. Kupelian V, Hayes FJ, Link CL, Rosen R, McKinlay JB. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 2008;93:3403-3410.
23. Lavallee B, Provost PR, Kahwash Z, Nestler JE, Belanger A. Effect of insulin on serum levels of dehydroepiandrosterone metabolites in men. Clin Endocrinol (Oxf) 1997;46:93-100.
24. Liou TH, Yang JH, Hsieh CH, Lee CY, Hsu CS, Hsu MI. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009;92:1960-1965.
25. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991;72:1242-1248.
26. Meyer C, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4630-4635.
27. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-1367.
28. Moran C, Knochenhauer E, Boots LR, Azziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 1999; 71:671-674.
29. Moran C, Renteria JL, Moran S, Herrera J, Gonzalez S, Bermudez JA. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome. Fertil Steril 2008;90:2310-2317.
30. Ozdemir S, Ozdemir M, Gorkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand 2010;89:199-204.
31. Piltonen T, Koivunen R, Morin-Papunen L, Ruokonen A, Huhtaniemi IT, Tapanainen JS. Ovarian and adrenal steroid production: regulatory role of LH/HCG. Hum Reprod 2002;17:620-624.
32. Roberge C, Carpentier AC, Langlois MF, Baillargeon JP, Ardilouze JL, Maheux P, Gallo-Payet N. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab 2007;293:E1465-1478.
33. Sanchez J, Perez-Heredia F, Priego T, Portillo MP, Zamora S, Garaulet M, Palou A. Dehydroepiandrosterone prevents age-associated alterations, increasing insulin sensitivity. J Nutr Biochem 2008;19:809-818.
34. Savastano S, Belfiore A, Guida B, Angrisani L, Orio F Jr, Cascella T, Milone F, Micanti F, Saldalamacchia G, Lombardi G et al. Role of dehydroepiandrosterone sulfate levels on body composition after laparoscopic adjustable gastric banding in pre-menopausal morbidly obese women. J Endocrinol Invest 2005;28:509-515.
35. Schunkert H, Hense HW, Andus T, Riegger GA, Straub RH. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. Am J Hypertens 1999;12:1140-1143.
36. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between non-obese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682-4688.
37. Slayden SM, Moran C, Sams WM Jr, Boots LR, Azziz R. Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001; 75:889-892.
38. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-1186.
39. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus working group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
40. Van Gaal L, Vansant G, Van Campenhout C, Lepoutre L, De Leeuw I. Apolipoprotein concentrations in obese subjects with upper and lower body fat mass distribution. Int J Obes 1989;13:255-263.
41. Volzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, Rosskopf D, Wallaschofski H. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 2010;33:45-53.
42. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163.
43. Zaadstra BM, Seidell JC, Van Noord PA, te Velde ER, Habbema JD, Vrieswijk B, Karbaat J. Fat and female fecundity: prospective study of effectofbody fat distributiononconception rates. BMJ 1993;306:484-487.